Akeso, Inc. (HKG:9926)
121.00
-0.90 (-0.74%)
At close: Jan 16, 2026
Akeso Revenue
Akeso had revenue of 1.41B CNY in the half year ending June 30, 2025, a decrease of -61.61%. This brings the company's revenue in the last twelve months to 2.51B, up 33.97% year-over-year. In the year 2024, Akeso had annual revenue of 2.12B, down -53.08%.
Revenue (ttm)
2.51B CNY
Revenue Growth
+33.97%
P/S Ratio
40.51
Revenue / Employee
827.26K CNY
Employees
3,035
Market Cap
111.46B HKD
Revenue Chart
* This company reports financials in CNY.
Revenue History
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Dec 31, 2024 | 2.12B | -2.40B | -53.08% |
| Dec 31, 2023 | 4.53B | 3.69B | 440.35% |
| Dec 31, 2022 | 837.66M | 612.03M | 271.26% |
| Dec 31, 2021 | 225.63M | - | - |
| Dec 31, 2020 | - | - | - |
| Dec 31, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2018 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
| Company Name | Revenue |
|---|---|
| JD Health International | 71.34B |
| BeOne Medicines AG | 38.69B |
| Alibaba Health Information Technology | 36.09B |
| Sino Biopharmaceutical | 33.49B |
| CSPC Pharmaceutical Group | 28.65B |
| WuXi Biologics | 21.98B |
| Hansoh Pharmaceutical Group Company | 14.45B |
| Innovent Biologics | 12.52B |
Akeso News
- 3 days ago - Akeso's Cadonilimab Outperforms PD-1 Inhibitors In Gastric Cancer; Stock Up - Nasdaq
- 10 days ago - Akeso Secures NMPA Label Update For Ivonescimab With Dual Survival Benefits In NSCLC - Nasdaq
- 5 weeks ago - Akeso Presents Positive Data Of Cadonilimab Regimen In Resectable Gastric Cancer At ESMO Asia 2025 - Nasdaq
- 2 months ago - Summit C-Suite Risks Success, Akeso Wins Either Way - Seeking Alpha
- 2 months ago - Akeso, Inc. (AKESF) Presents at 40th Annual Meeting of the Society for Immunotherapy of Cancer (SITC 2025) - Slideshow - Seeking Alpha
- 3 months ago - Akeso, Inc. (AKESF) Presents at ESMO Congress 2025 - Slideshow - Seeking Alpha
- 3 months ago - China’s Akeso gets share boost as data shows cancer drug’s benefits - South China Morning Post
- 4 months ago - Akeso's Ligufalimab Receives FDA Orphan Drug Designation For Acute Myeloid Leukemia - Nasdaq